

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Kerstin Kriegelstein
Application No. :
Filed : Herewith
For : USE OF TGF-BETA INHIBITORS FOR TREATING CEREBRAL
DISORDERS
Examiner :
Attorney's Docket : MBP-005XX

Group Art Unit:

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Box PCT, Assistant Commissioner for Patents, Washington,
D.C. 20231 on _____.

By: _____
Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant

INFORMATION DISCLOSURE STATEMENT

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

It is desired to cite for the record in this application the
enclosed references listed on the attached copy of PTO Form #1449. The
paragraph(s) marked below are applicable to this Information Disclosure
Statement.

- [X] (1) Pursuant to 37 C.F.R. § 1.97(b)(1) and (2), the attached
Information Disclosure Statement is being filed within three
months of the filing date of the above identified national
application or within three months of the date of entry of the
national stage as set forth in 37 C.F.R. § 1.491 of the above
identified application. Accordingly, applicant(s) believes that
no fee or statement under 37 C.F.R. § 1.97(e) is required.

Application No.
Filed: Herewith
Group Art Unit:

- [] (2) Pursuant to 37 C.F.R. § 1.97(b)(3), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action on the merits. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (3) Pursuant to 37 C.F.R. § 1.97(b)(4), applicant(s) believes the attached Information Disclosure Statement is being filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, applicant(s) believes that no fee or statement under 37 C.F.R. § 1.97(e) is required.
- [] (4) Pursuant to 37 C.F.R. § 1.97(c), the attached Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by:
- [] a statement under 37 CFR § 1.97(e); or
- [] the fee set forth in § 1.17(p).

PETITION UNDER 37 CFR § 1.97(d)

- [] (5) Pursuant to 37 CFR § 1.97(d), applicant(s) hereby petitions the Commissioner to consider the attached Information Disclosure Statement which is being filed on or before payment of the issue fee. This petition is accompanied by a statement under 37 C.F.R. § 1.97(e) and the petition fee set forth in 37 C.F.R. § 1.17(i).

STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)

- [] (6) The undersigned hereby states that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

STATEMENT UNDER 37 C.F.R. § 1.97(e)(2)

- [] (7) The undersigned hereby states that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the attached Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Application No.
Filed: Herewith
Group Art Unit:

The filing of this Information Disclosure Statement is not a representation by the undersigned as to personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.


If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy 37 C.F.R. § 1.98(a)(3) even if in a foreign language because the codes are the same in all languages. However, applicant(s) does not necessarily adopt the position reflected by that report.

The references cited herein were cited in the International Search Report mailed December 9, 1999 and the International Preliminary Examination Report mailed December 29, 2000 for International Application No. PCT/EP99/06433 filed September 1, 1999.

The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 23-0804. Triplicate copies of this letter are enclosed.

Respectfully submitted,

KERSTIN KRIEGELSTEIN

By: 

Charles L. Gagnebin III
Registration No. 25,467
Attorney for Applicant

WEINGARTEN, SCHURGIN,
GAGNEBIN & HAYES LLP
Ten Post Office Square
Boston, Massachusetts 02109

Telephone: (617) 542-2290
Telecopier: (617) 451-0313

Date: 3-2-1

CLG/jde/243732
Enclosures

09/786435

 Rec'd PCT/PTO
 Date: March 2, 2001
 Page 1 of 1

02 MAR 2001

 Form PTO-1449
 (REV. 8-83)

 U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

 ATTY. DOCKET NO.
 MBP-005XX

APPLICATION NO.

APPLICANT: KERSTIN KRIEGLSTEIN

FILING DATE: Herewith

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
	5,399,487**	03/21/95	Buténas et al.	435	13	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
EP 0 181 267 A2**	05/14/86	EPO			X
WO 95/10611**	04/20/95	WIPO			X
WO 93/19783**	10/14/93	WIPO			X

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	Transforming growth factor-betas in neurodegenerative disease, Kathleen C. Flanders et al., <u>Progress in Neurobiology</u> , Vol 54, No. 1, Jan. 1998, pp. 71-85. **
	Distinct modulatory actions of TGF-beta and LIF on neurotrophin-mediated survival of developing sensory neurons, Kerstin Kriegelstein et al., <u>Neurochemical Research</u> , Vol. 21, No. 7, July 1996, pp. 843-850. **
	TGF-β1 protects hippocampal neurons against degeneration caused by transient global ischemia: Dose-response relationship and potential neuroprotective mechanisms, P. Henrich-Noack et al., <u>Stroke</u> , Vol. 27, No. 9, Sept. 1996, pp. 1609-1614. **

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXPRESS MAIL NO.

EL 634679376 US